Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer

Clinical Colorectal Cancer

Volumn 8, Issue 1, 2009, Pages 15-21

  Bhushan, Shriya ^a   McLeod, Howard ^a   Walko, Christine M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

5 fluorouracil; Cetuximab; Dihydropyrimidine dehydrogenase; ERCC1; Irinotecan; Oxaliplatin; Thymidylate synthase; UGT1A1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE; IRINOTECAN; MESSENGER RNA; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; THYMIDYLATE SYNTHASE;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLON BIOPSY; COLORECTAL CANCER; DIARRHEA; DRUG COST; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NEUTROPENIA; ONCOGENE K RAS; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENETICS; PREDICTION; PROGNOSIS; RECEPTOR GENE; REVIEW; STOMATITIS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 61349194968     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.003     Document Type: Review

References (36)

1. Thrall M, Wood P, King V, et al. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2000; 46:873-81.
2. Sobrero A, Guglielmi A, Grossi F, et al. Mechanism of action of fluoropy-rimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000; 27(5 suppl 10):72-7.
3. Lehman NL. Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 2002; 11:1775-87.
4. Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-6.
5. Marsh S, McLeod H. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 2001; 1:175-8.
6. Uetake H, Ichikawa W, Takechi T, et al. Relationship between intratumoral dihy-dropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 1999; 5:2836-9.
7. Yen-Revello JL, Goldberg RM, Mcleod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008; 14:8-13.
8. Kralovánszky J, Adleff V, Hitre E, et al. Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer. Magy Onkol 2007; 51:113-25.
9. Klein CE, Gupta E, Reid JM, et al. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther 2002; 72:638-47.
10. Mathijssen R, Alphen R, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182-94.
11. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43-7.
12. Hoskins J, Goldberg R, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99:1290-5.
13. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25(2 suppl 5):4-12.
14. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1:22-33.
15. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25:1247-54.
16. Park DJ, Stoehlmacher J, et al. ERCC1 polymorphism is associated with differential ERCC1 mRNA levels. Proc Am Assoc Cancer Res 2002; 43:321 (Abstract 1591).
17. Liévre A, Bachet J, et al. KRAS mutation status is predictive of response to cetux-imab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5.
18. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5.
19. Lievre A, Bachet JB, Boige V, at al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-9.
20. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-9.
21. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-15.
22. Frattini M, Saletti P, Romagnani E. et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-45.
23. Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancer. Mol Cancer 2003; 2:41.
24. Lothe RA, Peltomaki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993; 53:5849-52.
25. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Eng J Med 2000; 342:69-77.
26. Ribic C, Sargent D, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57.
27. Koopman M, Kortman GA, Mekenkamp L, et al. Use of microsatellite instability in non-hereditary advanced colorectal cancer to predict response to chemotherapy and overall survival: a study of the Dutch Colorectal Cancer Group. J Clin Oncol 2007; 25(18 suppl):192s (Abstract 4118).
28. Marsh S, McKay JA, Cassidy J, et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2003; 19:383-6.
29. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyridine dehydrogenase, thy-midylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-7.
30. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitu-mumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34.
31. Sartire-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25:3238-45.
32. Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetux-imab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008; 26:1427-34.
33. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97:981-9.
34. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleo-tide polymorphism within the 5' tandem repeat polymorphism of the thy-midylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63:2898-904.
35. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of the thymidylate synthase gene. Cancer Res 2003; 63:6004-7.
36. Uchida K, Hayashi K, Kawakami K, et al. Loss of heterozygosity at the thy-midylate synthase (TS) locus on chromosome 18 affects tumor response and surivival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004; 10:433-9.